新桥生物宣布,其全球性、随机二期临床研究已完成首例患者给药。该研究旨在评估Givastomig与免疫化疗联合方案,用于一线治疗转移性胃癌患者的疗效与安全性。
新桥生物宣布,其全球性、随机二期临床研究已完成首例患者给药。该研究旨在评估Givastomig与免疫化疗联合方案,用于一线治疗转移性胃癌患者的疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.